Cellular and molecular gastroenterology and hepatology · 2026
Bile Acid Detergency as Determinant of Liver Pathology in a Humanized Mouse Model of Progressive Familial Intrahepatic Cholestasis Type 3.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ke Lixin, Mulder Niels L, Hovingh Milaine V, Havinga Rick, Weersing Ellen, de Vries Hilde D, de Bruyn Krisztina, Ustyantsev Kirill, Berezikov Eugene, Bloks Vincent W, Attema Brecht, Worthmann Anna, Heeren Joerg, Wolters Justina C, Tiessen-Thomas Rachel, Verkade Henkjan J, Kuipers Folkert, de Boer Jan Freark
Аннотация
BACKGROUND & AIMS: Progressive familial intrahepatic cholestasis type 3 (PFIC3) is caused by impaired activity of ABCB4 that transports phosphatidylcholines (PC) from hepatocytes into bile. Abcb4-knockout (KO) mice have been generated, but hydrophilic muricholic acids in their bile acid (BA) pool may limit pathology and thereby hamper translation to human PFIC3. Therefore, we addressed whether Abcb4 knockdown (Abcb4-KD) in the livers of Cyp2c70-KO mice with a human-like BA composition leads to liver pathology that more closely resembles human PFIC3.
METHODS: Expression of Abcb4 gene was suppressed in livers of Cyp2c70-KO/L-Cas9tg mice and control-Cas9tg mice using CRISPR/Cas9-technology to assess short- and long-term consequences. The BA sequestrant colesevelam was mixed into the chow diet (2% w/w) of Cyp2c70-KO mice with or without Abcb4-KD, and the effects were evaluated after 6 weeks.
RESULTS: Abcb4-KD strongly reduced biliary phospholipid:BA ratios in both Cyp2c70-KO and control mice. However, plasma transaminases elevations, liver fibrosis, and ductular reactions were markedly aggravated by Abcb4-KD in the context of a human-like BA composition. Importantly, the biliary lipid compositions differed markedly between the 2 Abcb4-KD models. Reduced biliary PC and increased concentrations of lysophosphatidylcholine, sphingomyelin, and ceramide were associated with the severity of liver disease only in Cyp2c70-KO/Abcb4-KD mice. Gene set enrichment analysis indicated that epithelial-mesenchymal transition was induced in the livers of Cyp2c70-KO/Abcb4-KD mice compared with control Abcb4-KD mice. BA sequestration reduced biliary BA secretion rates and mitigated liver pathology in Cyp2c70-KO/Abcb4-KD mice.
CONCLUSIONS: The presence of a human-like BA composition profoundly aggravates liver pathology upon Abcb4 reduction in mice, conceivably due to the augmented extrusion of non-PC phospholipids by hydrophobic BAs from membranes into bile. This humanized PFIC3 model is anticipated to accelerate the development of novel therapies for PFIC3 and potentially other cholestatic liver diseases.
METHODS: Expression of Abcb4 gene was suppressed in livers of Cyp2c70-KO/L-Cas9tg mice and control-Cas9tg mice using CRISPR/Cas9-technology to assess short- and long-term consequences. The BA sequestrant colesevelam was mixed into the chow diet (2% w/w) of Cyp2c70-KO mice with or without Abcb4-KD, and the effects were evaluated after 6 weeks.
RESULTS: Abcb4-KD strongly reduced biliary phospholipid:BA ratios in both Cyp2c70-KO and control mice. However, plasma transaminases elevations, liver fibrosis, and ductular reactions were markedly aggravated by Abcb4-KD in the context of a human-like BA composition. Importantly, the biliary lipid compositions differed markedly between the 2 Abcb4-KD models. Reduced biliary PC and increased concentrations of lysophosphatidylcholine, sphingomyelin, and ceramide were associated with the severity of liver disease only in Cyp2c70-KO/Abcb4-KD mice. Gene set enrichment analysis indicated that epithelial-mesenchymal transition was induced in the livers of Cyp2c70-KO/Abcb4-KD mice compared with control Abcb4-KD mice. BA sequestration reduced biliary BA secretion rates and mitigated liver pathology in Cyp2c70-KO/Abcb4-KD mice.
CONCLUSIONS: The presence of a human-like BA composition profoundly aggravates liver pathology upon Abcb4 reduction in mice, conceivably due to the augmented extrusion of non-PC phospholipids by hydrophobic BAs from membranes into bile. This humanized PFIC3 model is anticipated to accelerate the development of novel therapies for PFIC3 and potentially other cholestatic liver diseases.